MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3487-3494

  Chu, Heying ^a   Chen, Xudong ^b   Wang, Huaqi ^a   Du, Yuwen ^c   Wang, Yuanyuan ^c   Zang, Wenqiao ^c   Li, Ping ^a   Li, Juan ^a   Chang, Jingxia ^a   Zhao, Guoqiang ^c   Zhang, Guojun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Luohe Medical College   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Migration; miR 495; MTA3; NSCLC; Proliferation

Indexed keywords

METASTASIS ASSOCIATED PROTEIN 3; MICRORNA; MIR 495; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; G1 PHASE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM PROTEINS;

EID: 84898817024     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1460-1     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80.
3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037-57.
4. Humphrey GW, Wang Y, Russanova VR, Hirai T, Qin J, Nakatani Y, et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem. 2001;276(9):6817-24.
5. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003;113(2):207-19.
6. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26(3):215-27.
7. Bowen NJ, Fujita N, Kajita M, Wade PA. Mi-2/NuRD: multiple complexes for many purposes. Biochim Biophys Acta. 2004;1677(1-3):52-7.
8. Li H, Sun L, Xu Y, Li Z, Luo W, Tang Z, et al. Overexpression of MTA3 correlates with tumor progression in non-small cell lung cancer. Plos One. 2013;8(6):1-8.
9. Brüning A, Makovitzky J, Gingelmaier A, Friese K, Mylonas I. The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol. 2009;132(1):33-8.
10. Bruning A, Juckstock J, Blankenstein T, Makovitzky J, Kunze S, Mylonas I. The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol. 2010;25(11):1447-56.
11. Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006;12(5):1479-86.
12. Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Bruning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther. 2008;7(9):1460-7.
13. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64(3):825-9.
14. Iguchi H, Imura G, Toh Y, Ogata Y. Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. Int J Oncol. 2000;16(6):1211-4.
15. Jang KS, Paik SS, Chung H, Oh YH, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 2006;97(5):374-9.
16. Xia Y, Chen Q, Zhong Z, Caihua X, Chen W, Liu B, et al. Down-regulation of MiR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. CELL Physiol Biochem. 2013;32(2):476-85.
17. Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, et al. Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013;8:166
18. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death and tumorigenesis. Br J Cancer. 2006;94(6):776-80.
19. Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010;9(16):1-10.
20. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309(5740):1519-24.
21. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet.2006;15(Spec No 1):R17-29
22. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem. 1992;61:441-70.
23. Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ. 2012;19(3):369-77.
24. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005;65(20):9287-93.
25. Ouyang W, Li J, Ma Q, Huang C. Essential roles of PI-3K/Akt/IKKbeta/ NFkappaB pathway in cyclinD1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006;27(4):864-73.
26. Zhang H, Singh RR, Talukder AH, Kumar R. Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway. Genes Dev. 2006;20(21):2943-8.
27. Mishra SK, Talukder AH, Gururaj AE, Yang Z, Singh RR, Mahoney MG, et al. Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway. J Biol Chem. 2004;279(31):32709-15.
28. Fujita N, Kajita M, Taysavang P, Wade PA. Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol Endocrinol. 2004;18(12):2937-49.
29. Chen Y, Miyazaki J, Nishizawa H, Kurahashi H, Leach R, Wang K. MTA3 regulates CGB5 and Snail genes in trophoblast. Biochem Biophys Res Commun. 2013;433(4):379-84.
30. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development. 2004;131(14):3469-79.
31. Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal. 2007;5:e010.
32. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369(6482):669-71.
33. Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995;15(7):3463-9.
34. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401(6750):297-300.
35. Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Muller HM, et al. Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene. 2004;23(23):4187-92.
36. Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, Evans MK. microRNA expression patterns reveal differential expression of target genes with age. PloS One. 2010;5(5):e10724
37. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PloS One. 2009;4(8):e6677.
38. Qin W, Ren Q, Liu T, Huang Y, Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013;587(9):1434-9.
39. Miao LJ, Huang SF, Sun ZT, Gao ZY, Zhang RX, Liu Y, et al. Mir-449 targets c-myc and inhibits NSCLC cell progression. FEBS Lett. 2013;587(9):1359-65.
40. Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, et al. Mir-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 2012;586(20):3761-5.